🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Will ivonescimab (bispecific antibody to PD1 and VEGF) replace PD(L)1 inhibitors in lung cancer? Phase III HARMONi-2 The Lancet compared first line ivonescimab to pembrolizumab in PD-L1+ NSCLC with significant PFS benefit (11.1 vs 5.8m, HR 0.51). thelancet.com/journals/lance…

Review on use of immunotherapy in less fit patients. IPSOS showed benefit of atezolizumab in pts with poor PS and advanced NSCLC. Poor PS represents a large subset of pts in clinic. Discussion here on this "invisible" population from AIOT panel in Italy. lungcancerjournal.info/article/S0169-…

The Clinical Trials team at Sligo University Hospital is about to open to recruitment the Gloriosa Clinical Trial for relapsed Ovarian Cancer (clinicaltrials.gov/study/NCT05445…). Good work Dr Lore Komanyano, and SUH Clinical Trials! Go Sligo! Cancer | University of Galway-HSE West North West HRB Clinical Research Galway CancerTrialsIreland 🌈

⏲️ BMI and survival with immune checkpoint inhibitors ACS Journal Cancer ➡️18,434 patients ➡️BMI >30 vs 20-24.9 ✅OS⬆️ with obesity HR: 0.69 (0.66–0.72) ⁉️except RCC 👉doi.org/10.1002/cncr.3… OncoAlert Dr Joseph McCollom DO #cancer #oncology #MedX

Are you planning on discussing a cancer randomized clinical trial in a conference, grand rounds, or any academic setting? Take a look at our Common Sense Oncology guideline for discussants of RCT! doi.org/10.1016/j.ejca…

📘Hepatitis B reactivation prophylaxis during immunosupressive treatments AGA 2025 Guideline 🔵In HbsAg ➖, antiHbc ➕ 🚨Anthracyclines, TKIs, TACE and steroids (mod/high dose, >4weeks) ➡️ moderate risk❗️ 👉doi.org/10.1053/j.gast… OncoAlert ESMO - Eur. Oncology ASCO EORTC

Most viewed in the last 7 days from JAMA Oncology: Cooling and compression were highly effective and significantly reduced the risk of high-grade chemotherapy-induced peripheral neuropathy. ja.ma/41IuiMB

Today is #DaffodilDay If passing our stations you can purchase a Daffodil Pin to support cancer patients and their families 🌼 ℹ️ cancer.ie

Frequently asked questions on surrogate endpoints in oncology: opportunities, pitfalls, and the way forward via Bishal Gyawali, MD, PhD, FASCO et al acrobat.adobe.com/id/urn:aaid:sc…

#ASCO25 lung cancer updates loading… stay tuned!!

Zongertinib in #HER2 NSCLC simultaneous publication NEJM with #AACR25 presentation by Dr. John Heymach. In previously treated HER2 TKD mt NSCLC, RR 71%, duration of response 14.1m, mPFS 12.4m. G3 AEs in only 17% - diarrhea in 56% of pts but only 1 single case of G3 or higher.

Honored to represent University Health Network and @PMCancerCentre at #AATS2025. Our ctDNA Lung DETECT Study adds to the growing evidence supporting the utility of ctDNA in early-stage NSCLC #AATS25 #AATS #ctDNA

I just joined the CryptoAgents allowlist. CryptoAgents by Eternal AI (EAI) is the first fully onchain PFP collection for AI agents. Like CryptoPunks but for agents. Minting May 21 on Ethereum. Secure your spot: eternalai.org

Looking forward to this weekend in ASCO in sunny Chicago! Bojan Macanovic @simonbarry1892 ASCO Zac

1st line encorafenib + cetuximab + mFOLFOX6 vs SOC in BRAF V600E-mCRC 🔎BREAKWATER: PFS + updated OS #ASCO25 👉ORR 65 vs 37 vs 43 % 👉mPFS 12.8 vs 7.1 vs 6.9 mo 👉mOS 30.3 vs 15.1 vs 19.1 mo 👉AE ≥3 76% vs 58 vs 15.7% 🧐 Really effective, new SOC in 1st line ESMO - Eur. Oncology

Delighted to recieve a Conquer Cancer, the ASCO Foundation YIA award. Special thanks to my mentors Jarushka Naidoo and bryanhennessy for the generosity of their time and expertise. Thanks in particular also to Dr Sinead Toomey and Irish Cancer Society Beaumont RCSI Cancer Centre ASCO

⁦Rami Manochakian MD, FASCO Cancer Education⁩ underlining principles in Oncology Education at #ASCO25 ⁦OncoAlert⁩

🔥NeoPancOne🇨🇦 ➡️mFFX in resectable PDAC ➡️exploring GATA6&subtypes ➡️mEFS &OS 16.3 &34.2mths ➡️1yr EFS 90% in GATA6 hi vs 50% lo ➡️1yr OS classical 95% vs.57% basal-like ⭐️Time to subtype upfront in all PDAC recognising plasticity OncoAlert #ASCO25 Ontario Institute for Cancer Research (OICR) Princess Margaret Cancer Centre

Our very own Dr. Peter Hosein (Peter Hosein, MD) presented "Is Pancreas Subtyping Ready for Prime Time?" at #ASCO25 in a panel discussion focused on #PancreaticCancer research findings. Learn more about our presence: Sylvester.org/ASCO2025.

Excellent summary slides for current evidence for pancreatic cancer treatment . Useful for quick reference. @asco #asco25 taken from talk by Dr Brian Wolpin 👍OncoAlert ONCO BRUNO